GlassScriptPhysician profile
Chad B Manuel
NPI 1316967367
$4,340.50
in general payments reported to CMS, 2019-2025
31 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $500 · 2021: $402 · 2022: $146 · 2023: $536 · 2024: $867 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.64 | 2019-2025 | Ozempic |
| Abbvie INC. | $643.54 | 2019-2025 | |
| Pfizer INC. | $604.62 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $251.75 | 2024-2025 | Rexulti |
| Philips North America LLC | $240.47 | 2019 | |
| Glaxosmithkline, LLC. | $235.74 | 2020-2025 | Shingrix, Arexvy |
| Antares Pharma, INC. | $193.67 | 2023-2025 | Xyosted, Tlando |
| Exact Sciences Corporation | $156.17 | 2024-2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $139.16 | 2019-2022 | |
| Abbott Laboratories | $133.28 | 2023 | Diamondback Coronary |
| Lilly USA, LLC | $126.11 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $102.19 | 2024-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $96.28 | 2024-2025 | Voquezna |
| Tolmar, INC. | $92.28 | 2024-2025 | Jatenzo |
| Teva Pharmaceuticals USA, INC. | $84.53 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.33 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $70.23 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.54 | 2024-2025 | |
| Allergan, INC. | $62.44 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.67 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $34.47 | 2024-2025 | Trintellix |
| Neos Therapeutics, LP | $31.22 | 2024 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.26 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $22.64 | 2019-2021 | |
| Lundbeck LLC | $22.58 | 2025 | Rexulti |
| Biogen, INC. | $21.45 | 2024 | Spinraza |
| Ethicon US, LLC | $20.03 | 2019 | |
| Phadia US INC. | $19.30 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.83 | 2025 | Jardiance |
| Upsher-Smith Laboratories LLC | $15.18 | 2025 | |
| Astellas Pharma US INC | $13.90 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.